Cellromax Science Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Operating Revenue	22,184	21,630
Other Revenue	-	-0
Revenue	22,184	21,630
Revenue Growth (YoY)	2.56%	-
Cost of Revenue	11,637	9,346
Gross Profit	10,547	12,284
Selling, General & Admin	7,100	6,228
Amortization of Goodwill & Intangibles	4.02	1.67
Other Operating Expenses	133.87	112.08
Operating Expenses	7,712	6,784
Operating Income	2,835	5,501
Interest Expense	-50.49	-37.78
Interest & Investment Income	780.22	1,376
Currency Exchange Gain (Loss)	-4.8	-2.83
Other Non Operating Income (Expenses)	-247.81	-1,783
EBT Excluding Unusual Items	3,313	5,052
Gain (Loss) on Sale of Investments	127.93	71.81
Gain (Loss) on Sale of Assets	10.82	11.85
Pretax Income	3,451	5,136
Income Tax Expense	484.82	1,319
Net Income	2,966	3,817
Net Income to Common	2,966	3,817
Net Income Growth	-22.29%	-
Shares Outstanding (Basic)	11	10
Shares Outstanding (Diluted)	11	10
Shares Change (YoY)	9.27%	-
EPS (Basic)	264.00	367.00
EPS (Diluted)	261.00	367.00
EPS Growth	-28.88%	-
Free Cash Flow	1,707	6,088
Free Cash Flow Per Share	150.16	585.32
Gross Margin	47.54%	56.79%
Operating Margin	12.78%	25.43%
Profit Margin	13.37%	17.65%
Free Cash Flow Margin	7.69%	28.15%
EBITDA	3,314	5,936
EBITDA Margin	14.94%	27.44%
D&A For EBITDA	478.45	435.41
EBIT	2,835	5,501
EBIT Margin	12.78%	25.43%
Effective Tax Rate	14.05%	25.68%
Advertising Expenses	639.1	484.04

Source: S&P Global Market Intelligence. Standard template. Financial Sources.